{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:49:36Z","timestamp":1787759376039,"version":"build-2784847793"},"reference-count":100,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:00:00Z","timestamp":1635033600000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Extended\u2010spectrum \u03b2\u2010lactamase (ESBL)\u2010producing Enterobacterales are a global threat to public health due to their antimicrobial resistance profile and, consequently, their limited available treatment options. Tazobactam is a sulfone \u03b2\u2010lactamase inhibitor with in vitro inhibitory activity against common ESBLs in Enterobacterales, including CTX\u2010M. However, the role of tazobactam\u2010based combinations in treating infections caused by ESBL\u2010producing Enterobacterales remains unclear. In the United States, two tazobactam\u2010based combinations are available, piperacillin\u2010tazobactam and ceftolozane\u2010tazobactam. We evaluated and compared the roles of tazobactam\u2010based combinations against ESBL\u2010producing organisms with emphasis on pharmacokinetic\/pharmacodynamic exposures in relation to MIC distributions and established breakpoints, clinical outcomes data specific to infection site, and considerations for downstream effects with these agents regarding antimicrobial resistance development. While limited data with ceftolozane\u2010tazobactam are encouraging for its potential role in infections due to ESBL\u2010producing Enterobacterales, further evidence is needed to determine its place in therapy. Conversely, currently available microbiologic, pharmacokinetic, pharmacodynamic, and clinical data do not suggest a role for piperacillin\u2010tazobactam, and we caution clinicians against its usage for these infections.<\/jats:p>","DOI":"10.1002\/phar.2623","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T13:40:03Z","timestamp":1635082803000},"page":"864-880","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The role of tazobactam\u2010based combinations for the management of infections due to extended\u2010spectrum \u03b2\u2010lactamase\u2010producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-458X","authenticated-orcid":false,"given":"Marguerite L.","family":"Monogue","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Texas Southwestern Medical Center Dallas Texas USA"},{"name":"Division of Infectious Diseases and Geographic Medicine University of Texas Southwestern Medical Center Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-6684","authenticated-orcid":false,"given":"Emily L.","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services University of Maryland Medical Center Baltimore Maryland USA"},{"name":"Department of Pharmacy Practice and Science University of Maryland School of Pharmacy Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Aitken","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Michigan Medicine Ann Arbor Michigan USA"},{"name":"Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_2_9_3_1","unstructured":"CDC.The biggest antibiotic\u2010resistant threats in the U.S. Centers for Disease Control and Prevention. Published November 14 2019. Accessed January 20 2020.https:\/\/www.cdc.gov\/drugresistance\/biggest\u2010threats.html."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05035-11"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.12480"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70780-7"},{"issue":"2","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2018.04.001","article-title":"Molecular \u03b2\u2010lactamase characterization of Gram\u2010negative pathogens recovered from patients enrolled in the ceftazidime\u2010avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: efficacies analysed against susceptible and resistant subsets","volume":"52","author":"Mendes RE","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01052-20"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-17"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky295"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy492"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01867.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1139\/w03-111"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.1-14.2004"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2000.tb00541.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1997.tb10267.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02635-15"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2017.0017"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1991"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.767"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01848-16"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108246"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056926"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.4.851"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.566"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01265-19"},{"key":"e_1_2_9_32_1","unstructured":"M100Ed31 | performance standards for antimicrobial susceptibility testing 31st edition.Clinical & Laboratory Standards Institute. Accessed August 12 2021.https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"e_1_2_9_33_1","unstructured":"EUCAST: clinical breakpoints and dosing of antibiotics. Accessed December 30 2019.http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1479"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky453"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.4137\/IDRT.S13820"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijabmr.IJABMR_28_16"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.4103\/1658-600X.179829"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.01.008"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.007"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.02.004"},{"issue":"5","key":"e_1_2_9_42_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","article-title":"Antimicrobial activity of ceftolozane\u2010tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013\u20132016) as part of the surveillance program: program to assess ceftolozane\u2010tazobactam susceptibility","volume":"24","author":"Shortridge D","year":"2017","journal-title":"Microb Drug Resist"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_2_9_44_1","first-page":"305","article-title":"Activity of ceftolozane\/tazobactam against Gram\u2010negative rods of the family Enterobacteriaceae and Pseudomonas Spp. isolated from onco\u2010hematological patients hospitalized in a clinical hospital in Poland","volume":"25","author":"Saran O","year":"2019","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1556\/1886.2019.00001"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.501"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.05.011"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2017.0266"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.06.002"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.005"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.05.025"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2017.06.008"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx009"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00160-19"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02747-15"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02513-12"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02309-18"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2014.180"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2210"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1647781"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.001"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05005-11"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00656-13"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06113-11"},{"key":"e_1_2_9_65_1","volume-title":"Determination of the tazobactam exposure required for piperacillin efficacy using a one\u2010compartment in vitro infection model","author":"VanScoy BD","year":"2016"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_A.9"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01752-10"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01590-12"},{"key":"e_1_2_9_70_1","unstructured":"Zosyn Package Insert. Published online May 2012. Accessed March 22 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050684s055s061_050750s016s020lbl.pdf."},{"key":"e_1_2_9_71_1","unstructured":"Zerbaxa Package Insert. Published online September 2020. Accessed March 22 2021.https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zerbaxa\/zerbaxa_pi.pdf."},{"key":"e_1_2_9_72_1","volume-title":"Development of a population model of tazobactam including high doses","author":"Muller A","year":"2016"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1733"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106299"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02093-19"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30403-7"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.12.1232.32706"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.11.007"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir790"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00135-13"},{"issue":"9","key":"e_1_2_9_82_1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin\u2010tazobactam for patients with extended\u2010spectrum \u03b2\u2010lactamase bacteremia","volume":"60","author":"Tamma PD","year":"2015","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2015.101"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00365-16"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153696"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1205"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.10.008"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky530"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-16.1.23"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"issue":"3","key":"e_1_2_9_92_1","first-page":"281","article-title":"Molecular mechanisms of carbapenem resistance in enterobacter cloacae clinical isolates from Korea and clinical outcome","volume":"42","author":"Lee Y","year":"2012","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_9_93_1","first-page":"616961","article-title":"\u03b2\u2010lactamase amplification and porin loss drive progressive \u03b2\u2010lactam resistance in recurrent ESBL Enterobacteriaceae bacteremia","author":"Shropshire WC","year":"2019","journal-title":"bioRxiv"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks368"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt044"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00838-16"},{"issue":"11","key":"e_1_2_9_97_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/ciy363","article-title":"Colonization with levofloxacin\u2010resistant extended\u2010spectrum \u03b2\u2010lactamase\u2010producing Enterobacteriaceae and risk of bacteremia in hematopoietic stem cell transplant recipients","volume":"67","author":"Satlin MJ","year":"2018","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00125-13"},{"key":"e_1_2_9_100_1","unstructured":"JMI Laboratories.SENTRY antimicrobial surveillance program. Accessed March 20 2021.https:\/\/sentry\u2010mvp.jmilabs.com\/."},{"key":"e_1_2_9_101_1","unstructured":"PranitaDT AitkenSL BonomoRA MathersAJ vanDuinD ClancyCJ.AMR guidance. Accessed March 22 2021.https:\/\/www.idsociety.org\/practice\u2010guideline\/amr\u2010guidance\/."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2623","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2623","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:40:36Z","timestamp":1761064836000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/phar.2623"],"URL":"https:\/\/doi.org\/10.1002\/phar.2623","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"2021-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}